2. Academic Validation
  3. A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma

A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma

  • J Med Chem. 2024 Sep 12;67(17):15428-15437. doi: 10.1021/acs.jmedchem.4c01053.
Sadhan Jana 1,  Jialin Shang 1,  Jun Young Hong 1,  Michael K Fenwick 1,  Rishi Puri 2,  Xuan Lu 1,  Ari M Melnick 3,  Meng Li 3,  Hening Lin 1 4
Affiliations

Affiliations

  • 1 Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States.
  • 2 College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, United States.
  • 3 Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York 10065, United States.
  • 4 Howard Hughes Medical Institute; Department of Chemistry and Chemical Biology; Department of Molecular Biology and Genetics Cornell University Ithaca New York 14853 United States.
PMID: 39191393 DOI: 10.1021/acs.jmedchem.4c01053
Abstract

Diffuse large B-cell lymphomas (DLBCLs) are heterogeneous cancers that still require better and less toxic treatments. SIRT3, a member of the Sirtuin family of NAD+-dependent protein deacylase, is critical for DLBCL growth and survival. A mitochondria-targeted SIRT3 small-molecule inhibitor, YC8-02, exhibits promising activity against DLBCL. However, YC8-02 has several limitations including poor solubility. Here, we report our medicinal chemistry efforts that led to an improved mitochondria-targeted SIRT3 Inhibitor, SJ-106C, achieved by using a triethylammonium group, which helps to increase both solubility and SIRT3 inhibition potency. SJ-106C, while still inhibiting SIRT1 and SIRT2, is enriched in the mitochondria to help with SIRT3 inhibition. It is more active against DLBCL than other solid tumor cells and effectively inhibits DLBCL xenograft tumor growth. The findings provide useful insights for the development of SIRT3 inhibitors and mitochondrial targeting agents and further support the notion that SIRT3 is a promising druggable target for DLBCL.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z